LFM-A13

Cas No.:	244240-24-2
Chemical Name:	LFM-A13
Synonyms:	2-Butenamide,2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-, (2Z)-;2-cyano-N-(2,5-dibromophenyl)-3-oxobutanamide;LFM-A13;(2Z)-dehydrocitral;(2Z)-N-(2,5-dibromophenyl)-2-cyano-3-hydroxybut-2-enamide;(2Z,4E)-3,7-dimethyl-2,4,6-octatrienal;(2Z,4E)-3,7-dimethyl-octa-2,4,6-trienal;2,4,6-Octatrienal, 3,7-dimethyl-;2,4,6-Octatrienal, 3,7-dimethyl-, (2E,4E)-;2,4,6-Octatrienal, 3,7-dimethyl-, (Z,E)-;CTK1C6787;CTK2A1469;CTK3C8780;dehydrocitral;trans-4,5-didehydro-neral;trans-dehydroneral;α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide;(2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide;a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide;(Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide;SMR001230714;alpha-Cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide;C11H8Br2N2O2;BiomolKI_000050;BiomolKI2_000056;Lopac0_000650;BMK1-F2;BSPBio_001239;MLS002153290;MLS006010694;GTPL9262;2-cyano-N-(2,5-dibromophenyl);HMS1362M21;HMS1792M21;HMS1990M21;HMS2235P16;HMS3403M21;HMS3414K07;HMS3678K07;BCP12817;3781AH;BS0111;s7734;(2Z)-2-Cyan-N-(2,5-dibromphenyl)-3-hydroxy-2-butenamid;(2Z)-2-Cyano-N-(2,5-dibromophényl)-3-hydroxy-2-buténamide;(2Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide;2-Butenamide, 2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-, (2Z)-;2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide;&α;-cyano-β-hydroxy-&β;-methyl-N-(2, 5-dibromophenyl)propenamide;(Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide(LFM-A13);2-Butenamide, 2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-;2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide;2Z-cyano-N-(2,5-dibromophenyl)3-hydroxy-2-butenamide;LFM-A13;2-CYANO-N-(2,5-DIBROMOPHENYL)-3-HYDROXY-2-BUTENAMIDE;α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide
SMILES:	BrC1C(NC(/C(=C(/C)\O)/C#N)=O)=CC(=CC=1)Br
Formula:	C11H8Br2N2O2
M.Wt:	360.001420974731
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.
In Vivo:	LFM-A13 (25, 50 and 100 mg/kg) shows no apparent toxicity to rats. LFM-A13 (50 mg/kg, three times a week, i.p.) attenuates DMBA-induced mammary tumorigenesis in mice. LFM-A13 alone or in combination with paclitaxel shows marked effect on the DMBA-induced breast tumor incidence, mean tumor numbers, average tumor weight, and size in BALB/c mice. LFM-A13 (50 mg/kg, three times a week, i.p.) significantly decreases PLK1, cyclin D1, CDK-4, P53 and Bcl-2 expression, but increases the expression of p21, IκB, Bax and caspase 3 expression in mice[3]. LFM-A13 (200 mg/kg) does not cause hematologic toxicity in rats. LFM-A13 (10 or 50 mg/kg, i.p.) exhibits anti-tumor effects dose dependently in the MMTV/Neu transgenic mouse model of breast cancer[4].
In Vitro:	LFM-A13 significantly inhibits BTK activity with an IC50 of 6.2 ± 0.3 μg/mL (= 17.2 ± 0.8 μM). The calculated Kis of LFM-A13 for BTK, JAK1, JAK3, IRK, EGFR and HCK are 1.4, 110, 148, 31.6, 166 and 214 μM. LFM-A13 (200 μM) markedly increases the chemosensitivity of ALL-1 cells to ceramide-induced apoptosis[1]. LFM-A13 (100 μM) suppresses Epo-induced phosphorylation of EpoR, Jak2, Btk, Stat5 and Erk1/2 in R10 cells. LFM-A13 (100 μM) inhibits auto-phosphorylation of Jak2, Tec and Btk rather than Lyn kinase auto-phosphorylation in COS cells[2]. LFM-A13 potently inhibits Plx1 with IC50 of 10 μM; also inhibits BRK, BMX, FYN and with IC50s of 267, 281, 240 and 215 μM[4].